- Original investigation
- Open Access
Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance
© Almeda-Valdes et al; licensee BioMed Central Ltd. 2010
- Received: 2 April 2010
- Accepted: 23 June 2010
- Published: 23 June 2010
Insulin resistance (IR) and related metabolic disturbances are characterized by low levels of adiponectin. High molecular weight adiponectin (HMWA) is considered the active form of adiponectin and a better marker of IR than total adiponectin. The objective of this study is to compare the utility of total adiponectin, HMWA and the HMWA/total adiponectin index (SA index) for the identification of IR and related metabolic conditions.
A cross-sectional analysis was performed in a group of ambulatory subjects, aged 20 to 70 years, in Mexico City. Areas under the receiver operator characteristic (ROC) curve for total, HMWA and the SA index were plotted for the identification of metabolic disturbances. Sensitivity and specificity, positive and negative predictive values, and accuracy for the identification of IR were calculated.
The study included 101 men and 168 women. The areas under the ROC curve for total and HMWA for the identification of IR (0.664 vs. 0.669, P = 0.74), obesity (0.592 vs. 0.610, P = 0.32), hypertriglyceridemia (0.661 vs. 0.671, P = 0.50) and hypoalphalipoproteinemia (0.624 vs. 0.633, P = 0.58) were similar. A total adiponectin level of 8.03 μg/ml was associated with a sensitivity of 57.6%, a specificity of 65.9%, a positive predictive value of 50.0%, a negative predictive value of 72.4%, and an accuracy of 62.7% for the diagnosis of IR. The corresponding figures for a HMWA value of 4.25 μg/dl were 59.6%, 67.1%, 51.8%, 73.7% and 64.2%.
The area under the ROC curve of the SA index for the identification of IR was 0.622 [95% CI 0.554-0.691], obesity 0.613 [95% CI 0.536-0.689], hypertriglyceridemia 0.616 [95% CI 0.549-0.683], and hypoalphalipoproteinemia 0.606 [95% CI 0.535-0.677].
Total adiponectin, HMWA and the SA index had similar utility for the identification of IR and metabolic disturbances.
- Insulin Resistance
- Receiver Operator Characteristic Curve
- Adiponectin Level
- Metabolic Disturbance
- Adiponectin Concentration
Adiponectin is a peptide hormone produced by adipose tissue, involved in glucose and lipid metabolism [1–4]. The high molecular weight form is considered the active fraction of adiponectin; for this reason it is considered a better marker of metabolic disturbances than total adiponectin [5–7].
The average plasma concentration of this hormone ranges between 5 and 10 μg/ml; levels vary according to sex, body fat distribution, and metabolic status . Men have approximately 15% lower levels compared to women . Adiponectin concentration is lower in obesity, specifically central obesity  and studies confirm that levels increase with weight loss . Low adiponectin concentrations have also been registered in individuals with coronary artery disease . Finally, persons with diabetes have lower concentrations of this hormone compared to non- diabetics; levels are also low in states of hyperinsulinemia and glucose intolerance. Moreover, when adjusting for weight and body fat percentage, insulin sensitivity is independently associated with the adiponectin concentration .
The quantification of insulin resistance is desirable in clinical practice since this metabolic state is a treatable precursor of diabetes mellitus . Established direct methods to quantify insulin sensitivity, such as the hyperinsulinemic euglycemic clamp, are complex and time consuming. Surrogate indexes are available, but there are no universal cutoff points to define IR. Adiponectin may be a useful marker for insulin resistance and a variable that can integrate the abnormalities of the metabolic syndrome. As yet, few studies have determined the utility of adiponectin for this purpose. In addition, it is not know whether the high molecular weight form is superior in the evaluation of IR. The aim of this study is to evaluate the utility of total adiponectin, HMWA and the SA index for the identification of IR and metabolic disturbances in a Mexican population.
Ambulatory subjects aged 20 to 70 yr were recruited between March and July 2008 in Mexico City. The population consisted of medium-income healthy workers without a personal history of metabolic abnormalities. To avoid confounding factors known to affect plasma adiponectin concentration the following exclusion criteria were applied: fever (temperature ≥ 38°C), hospitalization in the previous two weeks, known diabetes, arterial hypertension, dyslipidemia, coronary heart disease or a condition with equivalent risk (carotid disease, peripheral artery disease, and aortic aneurysm), congestive heart failure, stroke, chronic renal disease, active hepatic disease, chronic diseases or any other acute or chronic inflammatory illness. These criteria were evaluated by a questionnaire and in the case of diabetes, renal insufficiency and hypertension by the measurement of fasting glucose, serum creatinine and blood pressure. Subjects were also excluded if they were on any medication known to affect the metabolic profile (anti-hypertensives, statins, fibrates, metformin, thiazolidinediones, and salicylic acid). The Ethics Committee approved the protocol and all participants gave written informed consent.
A questionnaire was administered to all participants; demographic data and medical history including smoking habit were obtained. Height, weight, waist circumference, and blood pressure were measured. Blood pressure was measured twice, after a 5 minute rest between measurements, and the average value was used for data analysis. Blood samples were collected after a 9 to 12-hour fasting period, centrifugated, and refrigerated at -70°C. All assays were carried out on serum samples (except for adiponectin that was measured in plasma) in the laboratory of the Department of Endocrinology and Metabolism. This laboratory is certified by the External Comparative Evaluation of Laboratories Program of the College of American Pathologists. Glucose was measured using the glucose oxidase method (Boehringer Mannheim, Germany), total cholesterol, and triglycerides were measured using an enzymatic method (Boehringer Mannheim, Germany), HDL-cholesterol was measured after precipitation using phosphotungstic acid and Mg2+, low density lipoprotein (LDL)-cholesterol concentration was estimated by the Friedewald formula, plasma insulin was determined by a MEIA assay (Abbott Laboratories), total adiponectin and HMWA concentrations were measured using commercial assays (Millipore, Mexico).
Briefly, the HMWA assay is a sandwich ELISA. Firstly the adiponectin molecule is captured by a monoclonal anti-adiponectin antibody coating the wells; secondly a polyclonal anti-adiponectin antibody binds to the captured molecules. Finally, a streptavidin-horseradish peroxidase conjugate binds to this complex. The enzyme activity is measured spectrophotometrically at 450 nm. Prior treatment of the plasma samples removes hexameric and trimeric adiponectin allowing for the specific measurement of HMWA.
Obesity was defined as a BMI of at least 30 kg/m2, hypertriglyceridemia was considered present with a triglyceride level ≥ 150 mg/dl, hypoalphalipoproteinemia was defined as HDL-cholesterol < 40 mg/dl in men and < 50 mg/dl in women. IR was evaluated and considered present when either: 1) the homeostasis model assessment of insulin resistance (HOMA-IR) was ≥ 2.5; 2) insulin sensitivity (HOMA2%S) estimated by the HOMA2 calculator v2.2 (Diabetes Trials Unit, University of Oxford) was < 75%, and 3) the triglyceride/HDL-cholesterol index was ≥ 3. The MS was defined according to the National Education Cholesterol Education Program's Adult Treatment Panel III (ATP-III) and the International Diabetes Federation (IDF) criteria [15, 16].
Normally distributed data, identified using Kolmogorov-Smirnov test, were expressed as mean ± standard deviation (SD). Variables with a skewed distribution were reported as median [interquartile range] [IQR]. Differences between groups were analyzed with the U-Mann Whitney or Kruskal-Wallis tests. Spearman's correlation coefficients were used to explore the association between total adiponectin, HMWA and SA index and IR estimations. ROC curves were plotted and comparisons of the area under the curve were performed as described by De Long et al. using Stata version 10 (College Station, TX). Other statistical analyses were performed using SPSS Software version 15 (SPSS, Inc., Chicago IL.).
Characteristics of the study population
(n = 269)
(n = 101)
(n = 168)
40.1 ± 9.49
40.5 ± 10.15
39.9 ± 9.42
Systolic pressure (mmHg)
111.1 ± 15.13
115.2 ± 15.00
108.5 ± 14.30
Diastolic pressure (mmHg)
74.5 ± 11.55
77.7 ± 9.98
72.6 ± 11.84
BMI (kg/m 2 )
27.7 ± 4.26
27.7 ± 3.81
27.7 ± 4.72
4.92 ± 1.00
4.93 ± 0.58
4.91 ± 1.30
Plasma total adiponectin and HMWA levels in the study population
There was a close correlation between the concentration of total adiponectin and HMWA (r = 0.890, P < 0.001). There was also a moderate concordance between individuals with total and HMWA below and above percentile 50 (kappa = 0.732, P < 0.001).
Consistent with the results of previous studies [7, 9], total adiponectin and HMWA levels were higher in women than in men (total adiponectin 9.49 [5.31] vs. 6.85 [2.78] μg/ml, P < 0.001, HMWA 5.7 [4.25] vs. 3.5 [2.65] μg/ml, P < 0.001). Thirty two participants (22.8% of women) were post-menopausal. Adiponectin and HMWA concentrations did not differ between pre and post-menopausal women (total adiponectin 9.5 [4.72] vs. 9.9 [6.48] μg/ml, P = 0.122, HMWA 5.7 [3.90] vs. 6.5 [6.10] μg/ml, P = 0.067). Total adiponectin and HMWA concentrations were lower in obese vs. non-obese individuals (total adiponectin 7.56 [3.63] vs. 8.7 [4.40] μg/ml, P = 0.028, HMWA 4.10 [2.82] vs. 5.00 [3.90] μg/ml, P = 0.008).
Concentrations of total and HMWA in patients with and without the metabolic syndrome
All (n = 269)
Metabolic syndrome (n = 77)
No metabolic syndrome (n = 192)
Men (n = 101)
Metabolic syndrome (n = 30)
No metabolic syndrome (n = 71)
Women (n = 168)
Metabolic syndrome (n = 47)
No metabolic syndrome (n = 121)
All (n = 269)
Metabolic syndrome (n = 102)
No metabolic syndrome (n = 167)
Men (n = 101)
Metabolic syndrome (n = 45)
No metabolic syndrome (n = 56)
Women (n = 168)
Metabolic syndrome (n = 57)
No metabolic syndrome (n = 111)
Concentration of total and HMWA levels associated with insulin resistance
Correlation between total adiponectin, HMWA and SA index and estimators of IR
High Molecular Weight Adiponectin
Concentrations of total and HMWA in patients with and without insulin resistance
All (n = 269)
Insulin resistance (n = 100)
No insulin resistance (n = 169)
Men (n = 101)
Insulin resistance (n = 42)
No insulin resistance (n = 59)
Women (n = 168)
Insulin resistance (n = 58)
No insulin resistance (n = 110)
All (n = 269)
Insulin resistance (n = 156)
No insulin resistance (n = 113)
Men (n = 101)
Insulin resistance (n = 78)
No insulin resistance (n = 23)
Women (n = 168)
Insulin resistance (n = 78)
No insulin resistance (n = 90)
All (n = 269)
Insulin resistance (n = 123)
No insulin resistance (n = 146)
Men (n = 101)
Insulin resistance (n = 47)
No insulin resistance (n = 54)
Women (n = 168)
Insulin resistance (n = 76)
No insulin resistance (n = 92)
Utility of total adiponectin and HMWA for the identification of IR and metabolic disturbances
In addition, the area under the ROC curves for total adiponectin and HMWA were not significantly different for the identification of metabolic abnormalities; obesity (total adiponectin 0.592 [95% CI 0.510-0.673] vs. HMWA 0.610 [95% CI 0.531-0.690], P = 0.32); hypertriglyceridemia (total adiponectin 0.661 [95% CI 0.596-0.726] vs. HMWA 0.671 [95% CI 0.607-0.736], P = 0.504); and hypoalphalipoproteinemia (total adiponectin 0.624 [95% CI 0.555-0.692] vs. HMWA 0.633 [95% CI 0.564-0.702], P = 0.582).
AUC of total and HMWA for the identification of IR and related metabolic abnormalities
(n = 269)
(n = 168)
(n = 101)
IR by HOMA-IR
S A index
IR by triglyceride/HDL-cholesterol index
S A index
IR by HOMA2%S
S A index
S A index
S A index
0.672 [0.565-0. 780]
S A index
A total adiponectin level of 8.03 μg/ml was associated with a sensitivity of 57.6%, a specificity of 65.9%, a positive predictive value of 50.0%, a negative predictive value of 72.4%, and an accuracy of 62.7% for the diagnosis of IR using the HOMA-IR index. The corresponding figures for a HMWA level of 4.25 μg/dl were 59.6%, 67.1%, 51.8%, 73.7% and 64.2%, respectively. When using the triglyceride/HDL-cholesterol index, the sensitivity of a total adiponectin level of 7.76 μg/ml was 54.5%, specificity 80.5%, positive predictive value 79.4%, negative predictive value 56.2%, and accuracy 65.4%. The corresponding figures for a HMWA level of 4.65 μg/ml were 64.7%, 73.5%, 77.1%, 60.1%, and 68.4%, respectively. Finally, when considering the HOMA2%S value, a total adiponectin value of 8.25 μg/ml yielded a sensitivity of 52.4%, specificity 59.9%, positive predictive value 53.3%, negative predictive value 59%, and accuracy of 56.3%. The corresponding figures for a HMWA level of 4.25 μg/ml were 52%, 66.3%, 75.4%, 41.0%, and 56.7%.
In recent years, several markers have been proposed for the screening, diagnosis, and therapeutic monitoring of insulin resistant patients . However, all have problems that limit their use to research studies . Not one succeeds in integrating the global assessment of the metabolic abnormalities that may increase the risk for developing type 2 diabetes and cardiovascular outcomes. Adiponectin is a promising biomarker of insulin resistance. Low adiponectin levels are associated with the majority of the metabolic syndrome traits and are related to an increased risk for having type 2 diabetes [20, 21]. This hormone is not prone to degradation and is only minimally affected by diurnal variations, pre- vs. postprandial status, and acute infections. Adiponectin levels can be assessed by either of three variables: total adiponectin, HMWA and the SA index. Here, we compare the diagnostic properties of these variables for detecting insulin resistance (assessed using surrogate markers) and other metabolic abnormalities in a population composed of apparently healthy adults. Total adiponectin, HMWA and the SA index had similar utility for the identification of the metabolic abnormalities. Our results suggest that plasma total adiponectin may provide clinical information of the same diagnostic value as HMWA. This finding may stimulate the use of adiponectin in clinical and epidemiological settings because the measurement of total adiponectin is better standardized, cheaper and more accessible than the other two approaches.
The highly significant correlation with insulin resistance makes adiponectin a powerful marker for diabetic risk. Several groups have shown that a low adiponectin level predicts the incidence of diabetes in children  and adults from several ethnic backgrounds . Its high molecular weight form is the active fraction of adiponectin, is selectively down-regulated in IR states [5, 14], and has been proposed as the best approach to evaluate adiponectin concentrations. However, the studies that support this conclusion have a small sample size , are post hoc analysis of studies designed for other purposes  or include biased populations (i.e. individuals with cardiovascular disease) . For example, Basu et al. evaluated adiponectin complex distribution in 11 type 2 diabetic and 7 nondiabetic subjects. Total adiponectin was lower in the diabetic subjects primarily due to a reduction of HMWA . However, the limited sample size of this study does not allow for the evaluation of adiponectin or HMWA as a diagnostic test for IR. Hara et al. reported that HMWA was better than total adiponectin for the detection of IR . In this study, the population consisted of patients with diabetes or those who had had a coronary angiography. The authors estimated IR (by calculating the HOMA index) and they reported a greater area under the ROC curve for HMWA of 0.713 (95% CI 0.620-0.805) than that found for total adiponectin of 0.615 (95% CI 0.522-0.708, P = 0.016). In our study we investigated the utility of total vs. HMWA for the identification of IR and related metabolic disturbances in an adult Mexican cohort. This population had no factors known to interfere with adiponectin concentrations. Our results showed a similar area under the ROC curve for both total adiponectin 0.664 [95% CI 0.597-0.732] and HMWA 0.669 [95% CI 0.603-0.735], P = 0.743). The same conclusion was reached for all surrogate markers of insulin resistance. We believe that our results differ from previous reports because of the characteristics of the population under study. Our study sample is representative of persons in whom a clinical indicator of IR is needed for early identification of diabetes risk.
In addition, no difference between the three approaches was found in the areas under the ROC curves for the identification of other metabolic disturbances (obesity, hypertriglyceridemia, hypoalphalipoproteinemia and IR). These findings suggest that adiponectin is of value for the identification of IR and metabolic disturbances. If this turns out to be the case, adiponectin may be a marker for global metabolic status. For this reason we attempted to estimate an adiponectin threshold for the identification of IR. The cutoff points used had a reasonable sensitivity and specificity. Further studies are needed to assess the diagnostic performance of these cutoff points in other populations.
One of the disadvantages of adiponectin is that the assay for its measurement is not widely available and is expensive. In addition, the HMWA is even more expensive and difficult to implement compared to the total adiponectin method. However, adiponectin measurements may be useful in the future to identify patients at risk for metabolic alterations and to monitor treatment results.
The cross sectional design, the use of surrogate markers (instead of the euglucemic hyperinsulinemic clamp) to measure insulin action and a moderate sample size are the main limitations of our study.
In this study, total adiponectin was as useful as HMWA and the SA index in evaluating metabolic status. In addition, there was a similar association between total and HMWA in assessing IR and related metabolic abnormalities.
We express our gratitude to the laboratory personnel of the Department of Endocrinology and Metabolism of the Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán".
- Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem. 1996, 120: 803-812.View ArticlePubMedGoogle Scholar
- Chandran M, Phillips SA, Ciaraldi T, Henry RR: Adiponectin. More than just another fat cell hormone?. Diabetes Care. 1996, 26: 2442-2450. 10.2337/diacare.26.8.2442.View ArticleGoogle Scholar
- Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001, 7: 941-946. 10.1038/90984.View ArticlePubMedGoogle Scholar
- Menzaghi C, Trischitta V, Doria A: Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes. 2007, 56: 1198-1209. 10.2337/db06-0506.View ArticlePubMedGoogle Scholar
- Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, Nagai R, Kadowaki T: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006, 29: 1357-1362. 10.2337/dc05-1801.View ArticlePubMedGoogle Scholar
- Nakano Y, Tajima S, Yoshimi A, Akiyama H, Tsushima M, Tanioka T, Negoro T, Tomita M, Tobe T: A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res. 2006, 47: 1572-1582. 10.1194/jlr.D600010-JLR200.View ArticlePubMedGoogle Scholar
- Aso Y, Yamamoto R, Wakabayashi S, Uchida T, Takayanagi K, Takebayashi K, Okuno T, Inoue T, Node K, Tobe T, Inukai T, Nakano Y: Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes. 2006, 55: 1954-1960. 10.2337/db05-1525.View ArticlePubMedGoogle Scholar
- Salmenniemi U, Zacharova J, Ruotsalainen E, Vauhkonen I, Pihlajamäki J, Kainulainen S, Punnonen K, Laakso M: Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy expenditure, and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab. 2006, 90: 4216-4223. 10.1210/jc.2004-2289.View ArticleGoogle Scholar
- Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002, 51: 2734-2741. 10.2337/diabetes.51.9.2734.View ArticlePubMedGoogle Scholar
- Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF, Rotter JI, Guo X, Chen YD, Bryer-Ash M, Norris JM, Haffner SM: Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J Clin Endocrinol Metab. 2007, 92: 2665-2671. 10.1210/jc.2006-2614.View ArticlePubMedGoogle Scholar
- Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999, 257: 79-83. 10.1006/bbrc.1999.0255.View ArticlePubMedGoogle Scholar
- Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999, 100: 1473-1476.View ArticleGoogle Scholar
- Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hiperinsulinemia. J Clin Endocrinol Metab. 2001, 85: 1930-1935. 10.1210/jc.86.5.1930.View ArticleGoogle Scholar
- Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP: Identification of individuals with insulin resistance using routine clinical measurements. Diabetes. 2005, 54: 333-339. 10.2337/diabetes.54.2.333.View ArticlePubMedGoogle Scholar
- Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, National Heart, Lung, and Blood Institute; American Heart Association: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004, 109: 433-438. 10.1161/01.CIR.0000111245.75752.C6.View ArticlePubMedGoogle Scholar
- Alberti KG, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006, 23: 469-480. 10.1111/j.1464-5491.2006.01858.x.View ArticlePubMedGoogle Scholar
- DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44: 837-845. 10.2307/2531595.View ArticlePubMedGoogle Scholar
- Ferrannini E, Mari A: How to measure insulin sensitivity. J Hypertens. 1998, 16: 895-906. 10.1097/00004872-199816070-00001.View ArticlePubMedGoogle Scholar
- Muniyappa R, Lee S, Chen H, Quon MJ: Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008, 294: E15-26. 10.1152/ajpendo.00645.2007.View ArticlePubMedGoogle Scholar
- Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002, 360: 57-8. 10.1016/S0140-6736(02)09335-2.View ArticlePubMedGoogle Scholar
- Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N: Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab. 2006, 91: 3873-7. 10.1210/jc.2006-1158.View ArticlePubMedGoogle Scholar
- Cruz M, García-Macedo R, García-Valerio Y, Gutiérrez M, Medina-Navarro R, Duran G, Wacher N, Kumate J: Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care. 2004, 27: 1451-3. 10.2337/diacare.27.6.1451.View ArticlePubMedGoogle Scholar
- Yang WS, Chuang LM: Human genetics of adiponectin in the metabolic syndrome. J Mol Med. 2006, 84: 112-21. 10.1007/s00109-005-0011-7.View ArticlePubMedGoogle Scholar
- Basu R, Pajvani UB, Rizza RA, Scherer PE: Selective downregulation of the high molecular weight form of adiponectin in hiperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes. 2007, 56: 2174-2177. 10.2337/db07-0185.View ArticlePubMedGoogle Scholar
- Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE: Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004, 279: 12152-12162. 10.1074/jbc.M311113200.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.